Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center

Feng Yang ¹, Yecheng Xu ¹, Chen Jin ¹

⁰Department of Pancreatic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Surgery +

|

May 21, 2025

View abstract on PubMed

Summary

Neuro-Patch may reduce postpancreatectomy hemorrhage in pancreatic cancer surgery. Neoadjuvant chemotherapy improves survival for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing arterial divestment.

Area Of Science

Surgical Oncology
Gastroenterology
Vascular Surgery

Background

Limited data exists on prognostic factors and hemorrhage prevention after periarterial divestment for advanced pancreatic cancer.
Evaluating Neuro-Patch efficacy for preventing postpancreatectomy hemorrhage is crucial.
Assessing oncologic outcomes following periarterial divestment is needed.

Purpose Of The Study

To evaluate Neuro-Patch for preventing postpancreatectomy hemorrhage.
To explore oncologic outcomes in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing periarterial divestment.

Main Methods

Retrospective analysis of 125 patients with pancreatic ductal adenocarcinoma involving arteries.
Periarterial divestment performed on hepatic, celiac, and superior mesenteric arteries.
Analysis of surgical outcomes, including hemorrhage rates and survival.

Main Results

Neuro-Patch use significantly reduced postpancreatectomy hemorrhage (OR 0.073, P = .031).
Median overall survival was 20.6 months; 1- and 3-year survival rates were 73.2% and 22.9%.
Neoadjuvant chemotherapy and venous invasion were independent predictors of survival.

Conclusions

Neoadjuvant chemotherapy significantly improves survival and should be standard preoperative care.
Neuro-Patch may reduce postpancreatectomy hemorrhage risk.
Further randomized trials are needed to confirm Neuro-Patch efficacy and safety.